Chargement en cours...
A MEK/PI3K/HDAC inhibitor combination therapy for KRAS mutant pancreatic cancer cells
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive, metastatic disease with limited treatment options. Factors contributing to the metastatic predisposition and therapy resistance in pancreatic cancer are not well understood. Here, we used a mouse model of KRAS-driven pancreatic carcinog...
Enregistré dans:
| Publié dans: | Oncotarget |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Impact Journals LLC
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4599239/ https://ncbi.nlm.nih.gov/pubmed/26158412 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Chargement en cours...